Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transcription factor AP-1
transduces environmental signals to the transcriptional machinery. To ensure a quick response yet maintain tight control over AP-1 target genes, AP-1 activity is likely to be negatively regulated in nonstimulated cells. To identify proteins that interact with the Jun subunits of AP-1 and repress its activity, we developed a novel screen for detecting protein-protein interactions that is not based on a transcriptional readout. In this system, the mammalian guanyl nucleotide exchange factor (GEF) Sos is recruited to the Saccharomyces cerevisiae plasma membrane harboring a temperature-sensitive Ras GEF, Cdc25-2, allowing growth at the nonpermissive temperature. Using the Sos recruitment system, we identified new
c-Jun
-interacting proteins. One of these,
JDP2
, heterodimerizes with
c-Jun
in nonstimulated cells and represses AP-1-mediated activation.
...
PMID:Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. 915 8
The progesterone receptor (PR) contains two transcription activation function (AF) domains, constitutive AF-1 in the N terminus and AF-2 in the C terminus. AF-2 activity is mediated by a hormone-dependent interaction with a family of steroid receptor coactivators (SRCs). SRC-1 can also stimulate AF-1 activity through a secondary domain that interacts simultaneously with the primary AF-2 interaction site. Other protein interactions and mechanisms that mediate AF-1 activity are not well defined. By interaction cloning, we identified an AP-1 family member,
Jun dimerization protein 2
(JDP-2), as a novel PR-interacting protein. JDP-2 was first defined as a
c-Jun
interacting protein that functions as an AP-1 repressor. PR and JDP-2 interact directly in vitro through the DNA binding domain (DBD) of PR and the basic leucine zipper (bZIP) region of JDP-2. The two proteins also physically associate in mammalian cells, as detected by coimmunoprecipitation, and are recruited in vivo to a progesterone-inducible target gene promoter, as detected by a chromatin immunoprecipitation (ChIP) assay. In cell transfection assays, JDP-2 substantially increased hormone-dependent PR-mediated transactivation and worked primarily by stimulating AF-1 activity. JDP-2 is a substantially stronger coactivator of AF-1 than SRC-1 and stimulates AF-1 independent of SRC-1 pathways. The PR DBD is necessary but not sufficient for JDP-2 stimulation of PR activity; the DBD and AF-1 are required together. JDP-2 lacks an intrinsic activation domain and makes direct protein interactions with other coactivators, including CBP and p300 CBP-associated factor (pCAF), but not with SRCs. These results indicate that JDP-2 stimulates AF-1 activity by the novel mechanism of docking to the DBD and recruiting or stabilizing N-terminal PR interactions with other general coactivators. JDP-2 has preferential activity on PR among the nuclear receptors tested and is expressed in progesterone target cells and tissues, suggesting that it has a physiological role in PR function.
...
PMID:Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. 1210 Dec 39
Muscle cell differentiation is a result of a complex interplay between transcription factors and cell signaling proteins. Proliferating myoblasts must exit from the cell cycle prior to their differentiation. The muscle regulatory factor and myocyte enhancer factor-2 protein families play a major role in promoting muscle cell differentiation. Conversely, members of the AP-1 family of transcription factors that promote cell proliferation antagonize muscle cell differentiation. Here we tested the role of the
c-Jun
dimerization protein
JDP2
in muscle cell differentiation. Endogenous expression of
JDP2
was induced in both C2C12 myoblast and rhabdomyosarcoma (RD) cells programmed to differentiate. Ectopic expression of
JDP2
in C2C12 myoblast cells inhibited cell cycle progression and induced spontaneous muscle cell differentiation. Likewise, constitutive expression of
JDP2
in RD cells reduced their tumorigenic characteristics and restored their ability to differentiate into myotubes.
JDP2
potentiated and synergized with 12-O-tetradecanoylphorbol-13-acetate to induce muscle cell differentiation of RD cells. In addition,
JDP2
induced p38 activity in both C2 and RD cells programmed to differentiate. This is the first demonstration of a single transcription factor that rescues the myogenic program in an otherwise non-differentiating cancer cell line. Our results indicate that the
JDP2
protein plays a major role in promoting skeletal muscle differentiation via its involvement in cell cycle arrest and activation of the myogenic program.
...
PMID:Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells. 1217 23
The mitogen-activated kinases are structurally related proline-directed serine/threonine kinases that phosphorylate similar phosphoacceptor sites and yet, in vivo, they exhibit stringent substrate specificity. Specific targeting domains (kinase docking domains) facilitate kinase-substrate interaction and play a major role in substrate specificity determination. The c-Jun N-terminal kinase (JNK) consensus docking domain comprises of a KXXK/RXXXXLXL motif located in the delta-domain of the
c-Jun
N-terminal to the phosphoacceptor site. The
c-Jun
dimerization protein 2 is phosphorylated by JNK on Thr-148. Activating transcription factor 3 (ATF3) is a basic leucine zipper protein which is highly homologous to
c-Jun
dimerization protein 2 (
JDP2
), especially within the threonine/proline phosphoacceptor site, Thr-148. Nevertheless, ATF3 does not serve as a JNK substrate in vitro or in vivo. Using ATF3 and
JDP2
protein chimaeras, we mapped the JNK-docking domain within
JDP2
. Although a JNK consensus putative docking site is located within the
JDP2
leucine zipper motif, this domain does not function to recruit JNK to
JDP2
. A novel putative docking domain located C-terminally to the
JDP2
phosphoacceptor site was identified. This domain, when fused to the ATF3 heterologous phosphoacceptor site, can direct its phosphorylation by JNK. In addition, although the novel JNK-docking domain was found to be necessary for p38 phosphorylation of
JDP2
on Thr-148, it was not sufficient to confer
JDP2
phosphorylation by the p38 kinase.
...
PMID:Differential targeting of the stress mitogen-activated protein kinases to the c-Jun dimerization protein 2. 1222 89
The
c-Jun
dimerization protein,
JDP2
, is a member of the AP-1 (activating protein-1) family of the basic leucine zipper transcription factors.
JDP2
can bind 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element and cAMP-responsive element DNA response elements, resulting in the inhibition of transcription. Although the role of AP-1 in cell proliferation and malignant transformation is well established, the role of
JDP2
in this process is of subject to debate. On the one hand,
JDP2
was shown to inhibit cyclin D transcription and promote differentiation of skeletal muscle and osteoclast cells. On the other hand,
JDP2
was shown to partially transform chicken embryo fibroblast and was identified in a screen for oncogenes able to collaborate with the loss of p27kip cyclin-dependent inhibitor to induce lymphomas. Using cell transformation assays in NIH3T3 cells and injection of prostate cancer cell lines overexpressing
JDP2
into severe combined immuno-deficient (SCID) mice, we show for the first time the potential role of
JDP2
in inhibition of cell transformation and tumor suppression. The mechanism of tumor suppressor action of
JDP2
can be partially explained by the generation of inhibitory AP-1 complexes via the increase of JunB, JunD, and Fra2 expression and decrease of
c-Jun
expression.
...
PMID:The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. 1462 10
Paraoxonase 2 (PON2) is a member of the paraoxonases gene family. PON2 is ubiquitously present in cells, including macrophages, and it was shown to protect against cellular oxidative stress. The aim of the present study was to analyze mechanisms involved in PON2 expression during monocyte/macrophage differentiation. PON2 expression was analyzed in vitro in THP-1 cells differentiated with 1alpha,25-dihydroxyvitamin D3 and in vivo in mouse peritoneal macrophages (MPM) isolated at increasing time intervals after intraperitoneal thioglycollate injection. PON2 expression (mRNA and protein) and activity gradually increased during monocyte/macrophage differentiation, up to five fold and eight fold in vitro and in vivo, respectively. This effect was associated with a gradual increase in cellular superoxide anion production. Supplementation of vitamin E to Balb/C mice inhibited the reduced nicotinamide adenine dinuleotide phosphate (NADPH)-oxidase-dependent increase in cellular superoxide anion production by 50% and down-regulated PON2 mRNA expression and activity by 30 and 60%, respectively. Furthermore, PON2 expression was lower by nine fold in MPM isolated from P47(phox-/-) (inactive NADPH oxidase) mice, in comparison to MPM from control mice. PON2 expression was found to be regulated, at least in part, by the
transcription factor AP-1
, as suggested by decreased
JDP2
(AP-1 repressor) protein expression in the nucleus and by decreased PON2 expression in the presence of a Jun N-terminal kinase inhibitor (SP600125). The present study demonstrates, for the first time, that PON2 expression increases in monocytes during their maturation into macrophage as a result of NADPH-oxidase activation, and this process is partly regulated by the
transcription factor AP-1
. PON2 stimulation may represent a compensatory mechanism against the increase in cellular superoxide anion production and atherogenesis.
...
PMID:Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. 1554 23
JDP2
is a ubiquitously expressed nuclear protein that efficiently represses the activity of the
transcription factor AP-1
. Thus far, all studies of
JDP2
function have relied on the ectopic expression of the protein. In this study, we use a different approach: depletion of
JDP2
from cells. Specific depletion of
JDP2
resulted in p53-independent cell death that resembles apoptosis and was evident at 72 h. The death mechanism was caspase dependent as the cells could be rescued by treatment with caspase inhibitor zVAD. Our studies suggest that
JDP2
functions as a general survival protein, not only following UV-irradiation, as reported earlier, but also under normal culture conditions. Thus, our data support that
JDP2
is a cellular survival protein whose presence is necessary for normal cellular function.
...
PMID:Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis. 1602 68
The
c-Jun
dimerization protein 2,
JDP2
, is a member of the activating protein 1 (AP-1) family of transcription factors. Overexpression of
JDP2
has been shown to result in repression of AP-1-dependent transcription and inhibition of cellular transformation. Other studies suggested that
JDP2
may function as an oncogene. Here we describe the identification of CHOP10, a member of the CCAAT enhancer binding proteins, as a protein associating with
JDP2
. In contrast to the inhibition of transcription by
JDP2
,
JDP2
-CHOP complex strongly enhances transcription from promoters containing TPA response elements (TRE), but not from those containing cyclic AMP response elements (CRE). The association between
JDP2
and CHOP10 involves the leucine zipper motifs of both proteins, whereas, the basic domain of CHOP10 contributes to the association of the
JDP2
-CHOP10 complex with the DNA. DNA binding of
JDP2
-CHOP complex is observed both in vitro and in vivo. Finally, overexpression of
JDP2
results in increased cell viability following ER stress and counteracts CHOP10 pro-apoptotic activity.
JDP2
expression may determine the threshold for cell sensitivity to ER stress. This is the first report describing TRE-dependent activation of transcription by
JDP2
and thus may provide an explanation for the as yet unexplored oncogenic properties of
JDP2
.
...
PMID:TRE-dependent transcription activation by JDP2-CHOP10 association. 1846 34
JDP2
(
c-Jun
dimerization protein 2) is a member of the basic leucine zipper family of transcription factors that is ubiquitously expressed in all examined cell types.
JDP2
is phosphorylated on Thr148 by JNK (c-Jun N-terminal kinase) and p38 kinase, although the functional role of its phosphorylation is unknown. In the present paper we show that the
JDP2
protein level is dramatically reduced in response to serum stimulation, anisomycin treatment, ultraviolet light irradiation and cycloheximide treatment, all of which activate the JNK pathway. In addition, endogenous and overexpressed
JDP2
are phosphorylated in response to these stimuli. Replacement of Thr148 with an alanine residue stabilizes ectopically expressed
JDP2
in the presence of the stimuli; conversely, substitution with glutamic acid destabilizes it. Serum-induced phosphorylation and degradation of
JDP2
are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and MEK inhibitors (SB203580 and UO126) have no effect. In the presence of cycloheximide,
JDP2
is rapidly phosphorylated and degraded due to the combined effects of protein synthesis inhibition and activation of JNK. Pre-treatment of cells with SP600125 prior to cycloheximide treatment significantly prolongs the half-life of
JDP2
that is found mainly in the unphosphorylated form. Lastly, the proteasome inhibitor (MG132) rescues
JDP2
degradation following cycloheximide treatment and increases the expression of the
JDP2
phospho-mimetic T148E mutant. Collectively, these results suggest that phosphorylation of
JDP2
on thr148 by JNK targets it to the proteasome for degradation.
...
PMID:Phosphorylation of JDP2 on threonine-148 by the c-Jun N-terminal kinase targets it for proteosomal degradation. 2146 60
Extensive research has unraveled the molecular basis of learning processes underlying contextual fear conditioning, but the mechanisms of fear extinction remain less known. Contextual fear extinction occurs when an aversive stimulus that initially caused fear is no longer present and depends on the activation of the extracellular signal-regulated kinase (ERK), among other molecules. Here we investigated how ERK signaling triggered by extinction affects its downstream targets belonging to the activator protein-1 (AP-1) transcription factor family. We found that extinction, when compared to conditioning of fear, markedly enhanced the interactions of active, phospho-ERK (pERK ) with
c-Jun
causing alterations of its phosphorylation state. The AP-1 binding of
c-Jun
was decreased whereas AP-1 binding of JunD,
Jun dimerization protein 2
(
JDP2
) and ERK were significantly enhanced. The increased AP-1 binding of the inhibitory JunD and
JDP2
transcription factors was paralleled by decreased levels of the AP-1 regulated proteins c-Fos and GluR2. These changes were specific for extinction and were MEK-dependent. Overall, fear extinction involves ERK/Jun interactions and a decrease of a subset of AP-1-regulated proteins that are typically required for fear conditioning. Facilitating the formation of inhibitory AP-1 complexes may thus facilitate the reduction of fear.
...
PMID:ERK-associated changes of AP-1 proteins during fear extinction. 2146 87
1
2
Next >>